PsychedelicNewsBreaks Archive - Page 49 of 65

WednesdayMar 24, 2021 2:23 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech…

MondayMar 22, 2021 10:41 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology for the delivery of its novel deuterated tryptamine (“CYB003”), a potential therapy for treatment-resistant psychiatric disorders. “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of…

WednesdayMar 17, 2021 11:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…

WednesdayMar 17, 2021 9:49 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Subsidiary Has Ordered First Shipment of Functional Mushrooms

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) subsidiary Pure Mushrooms Corp. has placed its first order for functional mushrooms from a British Columbia co-packer. Pure Mushrooms will use the mushrooms to produce three products, which will be offered through the company’s online e-commerce store. Previously Pure Mushrooms had developed three premium formulations based on reishi, maitake and lion’s mane mushrooms. These formulations, which are delivered in convenient vegan capsules, will be the foundation of the upcoming new products. Rreishi and maitake formulations should go on sale in April, with the lion’s mane release slated for June. The announcement…

TuesdayMar 16, 2021 12:02 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties should visit https://ibn.fm/ZE9G5 to register for the event. The presentation will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To view the full press release, visit https://ibn.fm/ZWvHk About Cybin Inc. Cybin is a leading biotechnology company…

MondayMar 15, 2021 10:10 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference slated to take place from March 17-19, 2021. In addition, Drysdale will participate on the psychedelics panel beginning at 3:30 p.m. ET on Wednesday, March 17. Interested parties should visit https://ibn.fm/MjGa2 for more information regarding the event. The panel discussion will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To…

FridayMar 12, 2021 10:30 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Releases Refiled Financial Statements, MD&A

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announced that it has refiled its condensed interim consolidated financial statements and management's discussion & analysis ("MD&A") for the three- and six-month periods ended March 31, 2020, following a review by the British Columbia Securities Commission. In its earlier reports of the periods mentioned, Champignon reported intangible assets in connection with its acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Information regarding those acquisitions have been restated to correct for the accounting of those acquisitions. After review, it was determined that the reported intangible assets did not meet…

ThursdayMar 11, 2021 10:55 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Sells First Batch of Cannabis Oil Extracts to German Pharma Company

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it has sold its first shipment of cannabis oil extracts to a German pharmaceutical company. According to the update, Pure Extracts purchased Canadian grown, EU-GMP certified, dry cannabis flower and extracted it into 65% pure THC full spectrum oil (“FSO”) and 85% pure THC distillate. The extracts will be further processed in Germany into an ultra-pure form of THC for medicinal purposes. “It is gratifying to have had our concentrates selected by…

WednesdayMar 10, 2021 12:51 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care Psychedelics: Addressing the Global Mental Health Crisis. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Thursday, March 11, 2021. The presentation will be webcast live at https://ibn.fm/yLkYT and available for seven days following the event. To view the full press release, visit https://ibn.fm/Wpble About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic…

TuesdayMar 09, 2021 1:17 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Strategic LOI with ShroomBloom

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it signed a letter of intent (“LOI”) with ShroomBloom Labs/Floja Bioscience Inc. to enter into an agreement for the supply of psychedelic mushroom biomass. British Columbia-based ShroomBloom is a mushroom cultivator leveraging a unique growing method that uses a sustainable forest product to grow organic Psilocybe Azurescens, also known as Azures, one of the most potent psilocybin mushrooms ever found. Under the terms of the LOI, Pure Extracts would be granted “most…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

PsychedelicNewsBreaks